Brianna Goldenstein, PhD

Efficacy and Safety of Iclepertin (BI 425809) in Patients With Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Abstract: Introduction No effective pharmacological treatments are available for cognitive impairments in schizophrenia. Iclepertin (BI 425809), an inhibitor of glycine transporter-1, enh...

Brianna Goldenstein , PhD;

01/19/2023

Efficacy and Safety of Iclepertin (BI 425809) in Patients with Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Cognitive impairment is a major determinant of poor functional outcomes in schizophrenia. Currently, studies testing potential treatments for cognitive impairment have failed to demonstra...

Brianna Goldenstein , PhD;

10/26/2023